$31.00
5.29% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US05463X1063
Symbol
AXGN

AxoGen, Inc. Stock price

$31.00
+3.31 11.95% 1M
+19.94 180.29% 6M
-1.73 5.29% YTD
+14.60 89.02% 1Y
+21.02 210.62% 3Y
+13.49 77.04% 5Y
+25.95 513.86% 10Y
+30.57 7,122.74% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-1.73 5.29%

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.4b
Net debt
$12.4m
Cash
$35.8m
Shares outstanding
46.1m
Valuation (TTM | estimate)
P/E
negative | 104.6
P/S
6.7 | 6.3
EV/Sales
6.7 | 6.3
EV/FCF
700.1
P/B
11.8
Financial Health
Equity Ratio
51.0%
Return on Equity
-9.6%
ROCE
2.1%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$214.7m | $227.8m
EBITDA
$10.0m | $29.1m
EBIT
$3.9m | $3.1m
Net Income
$-2.1m | $13.7m
Free Cash Flow
$2.1m
Growth (TTM | estimate)
Revenue
18.7% | 21.6%
EBITDA
1,152.6% | 742.5%
EBIT
146.4% | 195.4%
Net Income
85.3% | 237.3%
Free Cash Flow
120.8%
Margin (TTM | estimate)
Gross
74.8%
EBITDA
4.7% | 12.8%
EBIT
1.8%
Net
-1.0% | 6.0%
Free Cash Flow
1.0%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
5.2%
Employees
452
Rev per Employee
$410.0k
Show more

Is AxoGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

AxoGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a AxoGen, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a AxoGen, Inc. forecast:

Buy
93%
Hold
7%

Financial data from AxoGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
215 215
19% 19%
100%
- Direct Costs 54 54
26% 26%
25%
161 161
17% 17%
75%
- Selling and Administrative Expenses 129 129
10% 10%
60%
- Research and Development Expense 27 27
4% 4%
13%
10 10
1,153% 1,153%
5%
- Depreciation and Amortization 6.06 6.06
20% 20%
3%
EBIT (Operating Income) EBIT 3.94 3.94
146% 146%
2%
Net Profit -2.10 -2.10
85% 85%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about AxoGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AxoGen, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx).
Positive
Reuters
about one month ago
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Positive
Seeking Alpha
about one month ago
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-...
More AxoGen, Inc. News

Company Profile

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Head office United States
CEO Michael Dale
Employees 452
Founded 1977
Website www.axogeninc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today